Exodus Point Capital Management, LP Bei Gene, Ltd. Transaction History
Exodus Point Capital Management, LP
- $16.4 Billion
- Q3 2024
A detailed history of Exodus Point Capital Management, LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 13,600 shares of BGNE stock, worth $2.63 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,600
Previous 35,275
61.45%
Holding current value
$2.63 Million
Previous $5.03 Million
39.34%
% of portfolio
0.02%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding BGNE
# of Institutions
244Shares Held
45.3MCall Options Held
258KPut Options Held
52.2K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.04 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.24 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$961 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$716 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...